This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Myelodysplastic Syndromes, MDS골수형성이상증후군

Contents and key points
ItemDetails
A. Classification codesICD-10: D46 (Myelodysplastic syndromes) | Special Copayment Reduction: V193 (Special Copayment Reduction for cancer: copayment 5% for 5 years from the registration date)
B. SynonymsMDS, myelodysplastic neoplasm (new 2022 WHO term), refractory anemia (former name), preleukemia, MDS after aplastic anemia, therapy-related MDS (t-MDS)
C. Adult onsetPresents mainly at age 60 or older, but secondary MDS related to chemotherapy or radiation therapy can also occur at a younger age. Anemia is the most common initial finding.
1. HistoryAfter early reports by Block et al. in 1953, the FAB classification (5 subtypes) was proposed in 1982, and through the 2001, 2016, 2022, and 2024 WHO classification revisions it shifted to a molecularly based classification.
2. CausesMostly of unknown cause (idiopathic); alkylating anticancer agents, topoisomerase II inhibitors, radiation, benzene exposure, and smoking are associated with secondary MDS.
3. GeneticsSomatic mutations detected in about 90%; SF3B1 (MDS with ring sideroblasts), TET2, DNMT3A, ASXL1, TP53, RUNX1, and SRSF2 are the most commonly mutated genes.
4. General epidemiologyAnnual incidence about 3~5 per 100,000 (30~40 at age 70 or older); Asians have an incidence about 2~4 times lower than Westerners, but a higher proportion of high-risk subtypes.
5. PathophysiologyMultistep clonal evolution: initial mutation acquisition in hematopoietic stem cells → clonal expansion → accumulation of additional mutations → ineffective hematopoiesis and progression to AML.
6. SymptomsFatigue and lethargy (anemia), susceptibility to infection (neutropenia), and bleeding and bruising (thrombocytopenia) are the 3 major symptoms; in some, cytopenias are found incidentally without symptoms.
7. SignsPallor (anemia), ecchymoses and petechiae (thrombocytopenia), splenomegaly (high-risk MDS), fever and signs of infection, rarely skin infiltration (leukemia cutis).
8. ScreeningPeripheral blood smear and bone marrow biopsy are needed in patients aged 40 or older with unexplained cytopenias; no specific screening test has been established.
9. DiagnosisBone marrow aspiration and biopsy (morphology, cytogenetics, NGS), peripheral blood smear, chromosome analysis (FISH), flow cytometry, and molecular panels are essential for integrated diagnosis.
10. TreatmentLow risk: EPO, transfusion, lenalidomide (5q-); high risk: azacitidine/decitabine (HMA), allogeneic hematopoietic stem cell transplantation; venetoclax combination is emerging as a new standard.
11. PrognosisIPSS-R very low risk median survival > 8 years; very high risk median survival < 1 year; AML progression rate about 5~10% for low risk, about 40% for high risk.
12. PreventionMinimizing carcinogenic exposure (benzene, reducing alkylating agents), regular blood follow-up after cancer treatment, and early evaluation of cytopenias in the elderly are the key prevention strategies.
13. ReferencesMyelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management … and 9 other papers

1. History

The history of myelodysplastic syndromes (MDS) begins in the early 20th century with the concept of "refractory anemia". In 1938, Rhoads and Barker first described "refractory anemia (refractory normoblastic anemia)", and in 1953, Block, Jacobson, and Bethard first reported a latent preleukemic state progressing to acute leukemia. In 1956, similar concepts were published under various names such as 'smoldering acute leukemia' and 'refractory anemia with excess blasts'. In the 1970s, the term "preleukemia" was used, and as the heterogeneity of this group of diseases was recognized, the need for systematic classification emerged.

The turning point in the history of MDS was the publication of the FAB (French-American-British) classification in 1982. The FAB cooperative group, including Bennett, Catovsky, Daniel, and others, formally recognized MDS for the first time as an independent disease group and classified it into 5 subtypes (RA, RARS, RAEB, RAEB-T, CMML) based on the percentage of blasts in the bone marrow and peripheral blood, the percentage of ring sideroblasts, and monocytosis. This classification served as the standard for clinical research for the next 20 years.

In 2001, when the WHO classification of hematopoietic neoplasms replaced FAB, RAEB-T (bone marrow blasts 20~30%) was reclassified as AML, and new subtypes such as multilineage dysplasia were added. In the 2016 WHO revision, molecular genetic data were integrated into the MDS classification for the first time, and MDS with SF3B1 mutation was recognized as an independent subtype. In the 2022 WHO 5th edition, MDS was renamed "myelodysplastic neoplasm", and the International Consensus Classification (ICC 2022) published at the same time also expanded subclassification based on molecular features. The exact incidence of MDS in Korea has not yet been sufficiently studied, but there are reports that the proportion of high-risk subtypes is higher in Asian patients than in Western patients.


2. Causes

Most MDS (about 85%) is idiopathic (de novo) of unknown cause, and the remaining about 15% is secondary. The most important cause of secondary (therapy-related) MDS is prior chemotherapy or radiation therapy. Alkylating agents (cyclophosphamide, chlorambucil, melphalan) tend to cause MDS associated with loss of chromosome 5 or 7 at 5~7 years after treatment. Topoisomerase II inhibitors (etoposide, doxorubicin) show an earlier pattern, causing t-MDS/AML associated with 11q23 or 21q22 rearrangements within 1~3 years after treatment. Radiation alone or combined with anticancer drugs is also associated with secondary MDS.

Benzene is an occupational carcinogen strongly associated with hematologic malignancies including MDS. Long-term benzene exposure in the paint industry, petroleum refining, chemical plants, shoe manufacturing, and so on greatly increases the risk of MDS. Smoking is also associated with MDS risk, with a risk about 1.4~1.5 times higher in smokers than in nonsmokers reported. Associations of some pesticides (especially organochlorine pesticides), fungicides, and herbicides with increased MDS risk have also been studied. Congenital bone marrow failure syndromes (Fanconi anemia, Shwachman-Diamond syndrome, Diamond-Blackfan anemia) can transform into MDS, so hereditary predisposition is also partly involved.


3. Genetics

With the spread of next-generation sequencing (NGS), one or more somatic mutations are detected in about 90% of MDS patients. The most commonly mutated genes are as follows.

SF3B1 (RNA splicing factor): found in about 25~30% and strongly associated with ring sideroblasts. MDS with SF3B1 mutation has a relatively favorable prognosis and is recognized as an independent diagnostic category (MDS with SF3B1 mutation) in the 2022 WHO classification. TET2 (DNA demethylase): found in about 25~30% and more common in the elderly. It is also the most common mutation in age-related clonal hematopoiesis (CHIP). DNMT3A (DNA methyltransferase): found in about 10~15% and, together with TET2, represents abnormal epigenetic regulation. ASXL1 (regulation of polycomb repressive complex): found in about 15~20% and associated with poor prognosis. TP53 (tumor suppressor gene): found in about 10~15%, associated with complex karyotype and therapy-related MDS, and has the worst prognosis. RUNX1, EZH2, SRSF2 are also each found at a frequency of 5~15%.

Cytogenetic abnormalities are observed in about 50% of MDS. The most common abnormalities are isolated deletion of the long arm of chromosome 5 (del(5q), about 15%), loss of chromosome 7 short arm (-7, about 10%), deletion of the long arm of chromosome 20 (del(20q), about 7%), and complex karyotype (3 or more abnormalities, about 10~15%). del(5q) MDS is a distinctive clinical subtype with an excellent response to lenalidomide. The IPSS-M (molecular IPSS) classification system integrates mutation information for 31 genes with cytogenetic data, providing more precise prognostic prediction than the existing IPSS-R.


4. General epidemiology

Overall, MDS is a clonal hematologic neoplasm that occurs in the elderly population. The incidence in the total population is about 3~5 per 100,000 per year, rising sharply to 30~40 per 100,000 at age 70 or older. In the United States, about 15,000~20,000 people are newly diagnosed each year. The median age at diagnosis is about 70~75, and about 10~15% are diagnosed under age 60. It is about 1.5~2 times more common in men than in women.

The incidence of MDS in Asians (including Koreans) is reported to be about 2~4 times lower than in Westerners. In Korea, 0.48 and 0.39 per 100,000 have been reported for men and women, respectively (under age 35). However, Asian MDS patients are characterized by a higher proportion of high-risk subtypes and an age at diagnosis about 10 years younger than Western patients. This is partly related to findings that 5q deletion and SF3B1 mutation are more common in Western patients (associated with low risk), and complex karyotype and TP53 mutation are also reported more frequently in the West, whereas chromosome 7 abnormalities are more common in Asian patients. The incidence of secondary MDS is increasing as the number of survivors after treatment of malignancies grows.


5. Pathophysiology

The pathophysiology of MDS is understood by the stepwise clonal evolution model. In the first step, a normal hematopoietic stem cell acquires an initial mutation (driver mutation). Mutations in epigenetic regulator genes such as TET2 and DNMT3A commonly occur as the first event, establishing clonal hematopoiesis (CHIP, Clonal Hematopoiesis of Indeterminate Potential). At this stage, a small clone exists without cytopenia. In the second step, acquisition of additional somatic mutations (splicing factors, TP53, RAS, RUNX1, etc.) accelerates clonal expansion and causes ineffective hematopoiesis in the bone marrow, and clinical MDS develops.

The core of the mechanism of ineffective hematopoiesis is that, through abnormally increased apoptosis of the MDS clone during differentiation, hematopoietic progenitors fail to differentiate into mature blood cells and are destroyed within the bone marrow. This explains the paradoxical situation (hypercellular marrow + cytopenia) that appears as cytopenia in peripheral blood. As an immune mechanism, T cell-mediated autoimmunity contributes to suppression of hematopoiesis in low-risk MDS. In the third step, acquisition of additional mutations such as TP53, FLT3, NPM1, and RAS mutations causes an increase in bone marrow blasts and transformation to AML. In high-risk MDS, activation of the WNT/β-catenin pathway and the FLT3/RAS/MAPK pathway contributes to progression to AML.


6. Symptoms

The symptoms of MDS vary with the degree of cytopenia and the blood cell lineages affected. Anemia is the most common symptom, with fatigue, lethargy, exertional dyspnea, and dizziness. Anemia often progresses slowly, so patients adapt to the symptoms and diagnosis may be delayed. With moderate or worse anemia (Hb < 10 g/dL), chest pain (worsening of underlying coronary artery disease), rapid pulse, headache, and poor concentration may occur.

Susceptibility to infection due to neutropenia can lead to recurrent and severe bacterial and fungal infections. In particular, the risk of severe infection rises markedly at an absolute neutrophil count (ANC) < 500/μL. Thrombocytopenia causes mucosal bleeding (gum bleeding, nosebleeds), easy bruising, menorrhagia, and rarely severe bleeding. Some patients have left upper quadrant discomfort and early satiety due to splenomegaly. Systemic symptoms such as weight loss, night sweats, and mild fever may accompany it, reflecting cytokine release related to cell proliferation. About 30% of patients are asymptomatic, and cytopenias are found incidentally on blood tests.


7. Signs

On physical examination, MDS patients show varying degrees of pallor (face, conjunctiva, palms, nail beds, etc.) reflecting the degree of anemia. Petechiae and ecchymoses due to thrombocytopenia are seen on the skin and mucosa (oral cavity, palate). Hemorrhagic spots are especially common on the skin of the lower limbs. In high-risk MDS or with disease progression, splenomegaly (about 15~20%) and hepatomegaly may be found, reflecting extramedullary hematopoiesis.

Fever suggests infection due to neutropenia and is accompanied by local signs depending on the site of infection (decreased breath sounds and dullness to percussion in pneumonia; erythema, warmth, and swelling in skin infection, etc.). Rarely, papules, nodules, and plaque-like skin lesions appear due to skin infiltration by MDS (myeloid sarcoma, leukemia cutis), an important finding suggesting high-risk MDS or transformation to AML. In severe anemia, signs of heart failure (lower limb edema, jugular venous distension, pulmonary crackles due to pulmonary edema) may appear, an important complication especially in elderly patients with underlying cardiopulmonary disease.


8. Screening

To date, there is no standardized screening program for the early detection of MDS in the general population. However, it is important to suspect MDS and actively evaluate it in various clinical situations. Unexplained cytopenia is the key clinical clue for suspecting MDS. MDS evaluation should be performed in the following cases: anemia (especially macrocytic) persisting for 3 months or longer that is not explained by iron, vitamin B12, or folate deficiency; unexplained neutropenia or thrombocytopenia; multilineage cytopenias.

In cancer survivors with a history of chemotherapy or radiation therapy, surveillance for cytopenias through regular blood tests is important for the early detection of secondary MDS. In particular, regular complete blood counts for at least 5~10 years after completion of treatment are recommended in patients who received treatment including alkylating agents or topoisomerase II inhibitors. In occupational groups with benzene or ionizing radiation exposure, regular blood tests should be performed as part of occupational health. In patients with congenital bone marrow failure syndromes (Fanconi anemia, Shwachman-Diamond, etc.), regular bone marrow examinations are recommended to monitor for progression to MDS.


9. Diagnosis

The diagnosis of MDS is made by a multistep approach integrating peripheral blood smear, bone marrow aspiration and biopsy, cytogenetic testing, and molecular genetic testing. The peripheral blood smear shows dysplastic findings (abnormal red cell morphology, hypersegmented neutrophils, giant platelets, lack of platelet granules). The degree of cytopenia and the blast percentage are assessed.

Bone marrow aspiration and biopsy are essential for confirming MDS and classifying its subtype. Morphologically, dysplastic findings (nuclear dysplasia, cytoplasmic dysplasia), the percentage of ring sideroblasts, and the blast percentage are evaluated. Cytogenetic testing (karyotype analysis, FISH) is central to diagnostic and prognostic classification, and conventional G-banding karyotype analysis is the standard. Characteristic abnormalities such as 1q abnormalities, del(5q), -7, and del(20q) are used to aid diagnosis and predict prognosis. Molecular gene panel testing based on next-generation sequencing (NGS) is now included in standard diagnosis to identify key gene mutations such as SF3B1, TET2, DNMT3A, ASXL1, TP53, SRSF2, and RUNX1. Flow cytometry is used as an adjunct to quantify dysplasia and accurately count blasts. IPSS-R (Revised International Prognostic Scoring System) and IPSS-M are used for treatment decisions and prognostic prediction.


10. Treatment

Treatment of MDS is determined by IPSS-R risk classification. In the lower-risk group (very low, low), symptomatic treatment and supportive care are central. For control of anemia, erythropoiesis-stimulating agents (ESA) (epoetin, darbepoetin) are effective in patients with low serum EPO levels. In transfusion-dependent patients, iron chelation therapy (deferasirox) is considered to prevent iron overload. In del(5q) MDS, lenalidomide is highly effective in achieving transfusion independence and cytogenetic remission (transfusion independence rate about 67%). Immunosuppressive therapy (antithymocyte globulin + cyclosporine) is effective in improving anemia in some young patients with lower-risk MDS.

In the higher-risk group (high, very high), hypomethylating agents (HMA) are the standard treatment. Azacitidine is the first-line standard treatment that delayed progression to AML and prolonged overall survival in a randomized clinical trial (AZA-001), and decitabine is also used as an alternative. Recently, combination of venetoclax (BCL-2 inhibitor) with azacitidine or decitabine has shown higher complete remission rates than HMA alone in high-risk MDS and is emerging as a new first-line treatment. Allogeneic hematopoietic stem cell transplantation (alloSCT) is a potentially curative option in high-risk MDS and is performed in patients with a suitable donor who are fit for transplantation. In TP53-mutated MDS, magliaparucitec, ellagic acid-based treatment, and transplantation are being studied.


11. Prognosis

The prognosis of MDS differs greatly by IPSS-R risk category. In the very low-risk group (Very Low), median survival is about 8.8 years, and the time to 25% risk of AML progression is about 14.5 years. In the low-risk group (Low), median survival is about 5.3 years. In the intermediate-risk group (Intermediate) it is about 3.0 years, in the high-risk group (High) about 1.6 years, and in the very high-risk group (Very High) about 0.8 years. Overall, the 2-year survival rate of untreated high-risk MDS is less than 20%.

Transformation to AML occurs in about 5~10% of the low-risk group and about 40~50% of the high-risk group. Biallelic loss of TP53 is the molecular feature with the worst prognosis, with a median survival of about 6 months. The IPSS-M molecular prognostic scoring system is reported to reclassify risk about 30~40% more precisely than the conventional IPSS-R and is especially useful for improving treatment decisions in patients in the IPSS-R intermediate-risk group. In patients who have successfully undergone allogeneic hematopoietic stem cell transplantation, the 5-year survival rate is 30~40%.


12. Prevention

Primary prevention of idiopathic MDS is directed at minimizing currently known risk factors. Blocking occupational benzene exposure is the most important preventive measure; in workplaces using benzene, strengthened ventilation, use of personal protective equipment, and use of safe substitute substances are recommended. Strict compliance with benzene exposure limits (under Korea's Occupational Safety and Health Act) is required. Stopping smoking is also known to contribute to reducing MDS risk, so smoking cessation is recommended. Minimizing unnecessary radiation exposure is important for both occupational and medical exposure.

For prevention of secondary MDS, it is important when planning chemotherapy to optimize alkylating agents (minimum effective dose) and to reduce the field and dose of unnecessary radiation. In cancer survivors who received anticancer treatment, early detection through regular blood tests contributes to improving the course of secondary MDS. Intervention strategies to prevent progression to MDS in carriers of age-related clonal hematopoiesis (CHIP) are currently in clinical trials. Because CHIP carriers have increased cardiovascular risk and hematologic cancer risk, regular blood follow-up with awareness of this and control of cardiovascular risk factors are recommended.


13. References

  1. Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(8):1307-1325. DOI: 10.1002/ajh.26984. PMID: 37288613.

  2. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465. DOI: 10.1182/blood-2012-03-420489. PMID: 22740453.

  3. Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evid. 2022;1(7):EVIDoa2200008. DOI: 10.1056/EVIDoa2200008. PMID: 36540032.

  4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232. DOI: 10.1016/S1470-2045(09)70003-8. PMID: 19230772.

  5. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465. DOI: 10.1056/NEJMoa061292. PMID: 17021321.

  6. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-1228. DOI: 10.1182/blood.2022015850. PMID: 35767897.

  7. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703-1719. DOI: 10.1038/s41375-022-01613-1. PMID: 35732831.

  8. Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (MEDALIST): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10252):709-717. DOI: 10.1016/S0140-6736(20)31502-X. PMID: 32888455.

  9. Hwang SM. Classification of myelodysplastic syndrome. Blood Res. 2020;55(S1):S44-S54. DOI: 10.5045/br.2020.S007. PMID: 32719179.

  10. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627. DOI: 10.1182/blood-2013-08-518886. PMID: 24030381.